Delving into the Latest Updates on Thrombotech Ltd. with Synapse

概览

关联

1

项与 Thrombotech Ltd. 相关的药物

THR-18

靶点

PAI-1

作用机制

PAI-1抑制剂

在研机构-

原研机构

Hadassah Foundation

在研适应症-

非在研适应症

急性缺血性卒中

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Thrombotech Ltd. 相关的临床试验

NCT01253512

/ Unknown status临床1/2期

Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)

This will be a randomized, double-blind, placebo-controlled, multi-center, multi-national, escalating dose, pilot study comparing two doses of THR-18 to placebo when administered to patients suffering acute ischemic stroke and treated with Tissue Plasminogen Activator (tPA).
The study hypothesis is that THR-18 will be safe and well tolerated in subjects suffering acute ischemic stroke and treated with Thrombolysis.

开始日期2011-03-01

申办/合作机构

Thrombotech Ltd.

100 项与 Thrombotech Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Thrombotech Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Thrombotech Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Thrombotech Ltd. 相关的转化医学

登录后查看更多信息